Has Alexander Glaser, MD received payments from drug or device companies?

Yes. Drug and device makers reported $33,933 in general payments to Alexander Glaser, MD across 101 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Alexander Glaser, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Alexander Glaser, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Alexander Glaser, MD

Urology · Glenview, ILNPI 1316207947

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,138 of the $33,933 with a category attached, or 74.1%. Procept Biorobotics Corporation accounts for 79.0% of it on its own, with 14 other manufacturers making up the rest. Among urology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$33,933in general payments, 2019–2025

Across 101 payments — averaging $335.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Procept Biorobotics Corporation$27K
Angiodynamics, Inc.$3K
Boston Scientific$2K
Olympus America Inc.$674
Neotract Inc.$593
Coloplast$367
plus $907 from 9 others

$142,765in research payments, 2019–2025

Across 33 payments — averaging $4326.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boston Scientific$88K
Urovant Sciences Inc$31K
Sumitomo Pharma America, Inc.$22K
Astellas Pharma Global Development$3K

What the payments were for

Consulting fees$25,13874%
Travel & lodging$3,25410%
Food & beverage$5,45516%
Education$880%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Procept Biorobotics Corporation	36	$26,811
Angiodynamics, Inc.	12	$2,846
Boston Scientific	24	$1,736
Olympus America Inc.	7	$674
Neotract Inc.	7	$593
Coloplast	1	$367
Calyxo, Inc.	2	$298
Valencia Technologies Corporation	1	$158
Laborie Medical Technologies Corp.	1	$136
Abbott	2	$115
Pfizer	4	$75
Richard Wolf Medical Instruments Corp.	1	$54
Johnson & Johnson	1	$33
E.r. Squibb & Sons, L.L.C.	1	$21
180 Medical, Inc.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

AquaBeam Robotic System$19,665
AQUABEAM SYSTEM$6,385
Nanoknife$2,647
GENERAL BPH$845
UroLift$492
TITAN$367
CVAC Aspiration System$298
iTIND System$279
LithoVue$170
eCoin Device Kit$158
Soltive$150
Optilume BPH Drug Coated Balloon Catheter$136

How this compares

$33,933 in reported general payments places this provider in the 90th percentile of 550 urology providers in Illinois.

See all urology providers in Illinois →

Medicare billing

Part B allowed, 2024

$188,406

Medicare patients

798

Services billed

1,874

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
MyrbetriqMirabegron	220	$165,237
GemtesaVibegron	62	$51,197
Tamsulosin Hcl	838	$13,050
Finasteride	550	$8,356
Trospium Chloride ErTrospium Chloride	69	$7,850
Potassium Citrate ErPotassium Citrate	43	$5,073
Dutasteride	81	$3,989
Silodosin	27	$3,087
Oxybutynin Chloride ErOxybutynin Chloride	97	$3,045
Methenamine Hippurate	29	$2,708
Testosterone	16	$2,127
Solifenacin Succinate	49	$2,094
Alfuzosin Hcl ErAlfuzosin Hcl	86	$2,024
Cefpodoxime Proxetil	30	$1,266
Doxazosin Mesylate	26	$310

Paid to pharmacies, not to this prescriber.

Other urology in Glenview

James KearnsGlenview$31K
Kristian NovakovicGlenview$19K
Mark BrandtPark Ridge$1.3M
Aaron BergerChicago Ridge$583K
Gary SteinbergChicago$529K
Simone CrivellaroChicago$526K
Brian HelfandChicago$517K
Ashley RossChicago$404K
Kevin McVarySpringfield$372K
Richard HarrisMelrose Park$363K

See the full list for Illinois →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →